ARTICLE | Finance
With €75M round, SparingVision brings mutation-agnostic therapies to clinic
Financing co-led by Jeito, UPMC also gives French gene therapy company optionality for further deals
September 14, 2022 9:06 PM UTC
Having built out its ophthalmic gene therapy pipeline via business development, SparingVision is now focusing its newly raised capital on driving those programs into the clinic.
SparingVision S.A.S. raised €75 million ($76.3 million) in a series B round co-led by existing investors Jeito Capital and UPMC Enterprises, bringing the biotech’s total capital raised to €119.5 million...